Q3 2025 Geron Corp Earnings Call Transcript
Key Points
- Geron Corp (GERN) reported a net product revenue of $47.2 million for the third quarter, showing growth compared to the previous year.
- The company has a strong cash position of approximately $420 million, which is deemed sufficient to support its commercial and medical affairs initiatives.
- Geron Corp (GERN) has expanded its prescribing accounts by 15% in the quarter, adding approximately 150 new ordering accounts.
- The company completed its first shipment of RYTELO to Germany under a name patient early access program, preparing for commercialization in select EU markets in 2026.
- Geron Corp (GERN) has a robust pipeline with ongoing clinical trials, including the fully enrolled phase 3 trial in relapsed refractory myelofibrosis, with interim analysis expected in the second half of 2026.
- Demand for RYTELO was down 3% compared to the last quarter, with new patient starts not offsetting discontinuations.
- The company faces challenges in establishing RYTELO as a second-line therapy and educating healthcare providers on its use.
- Geron Corp (GERN) reported increased operating expenses, with selling, general, and administrative expenses rising to $39 million from $36 million in the previous year.
- The company is experiencing high inventory levels at distributors, which could impact future sales.
- There is a need for increased awareness and education among healthcare providers to drive the adoption of RYTELO, which may take time to achieve.
Hello and welcome to the Geron Corporation third-quarter 2025 earnings call. (Operator Instructions) I would now like to turn the call over to Dawn Schottlandt, Senior Vice President, Investor Relations and Corporate Affairs. You may begin.
Good morning, everyone. Welcome to the Geron Corporation third-quarter 2025 earnings conference call.
Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those relating to the launch, commercial opportunity, and therapeutic potential of RYTELO; anticipated clinical and commercial events and related timelines; the sufficiency of Geron's financial resources; and other statements that are not historical facts. Actual events or results could differ materially.
Therefore, I refer you to the discussion under the heading, Risk
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
